These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 39321318)

  • 1. Design, Synthesis, and Biological Evaluation of Covalently Mucoadhesive Derivatives as Nonsystemic Intestine-Targeted TGR5 Agonists.
    Zhao S; Wang L; Huang X; Xiao Y; Li M; Huang X; Chen X; Li S; Xie J; Liu P; Wang YD; Chen WD
    J Med Chem; 2024 Oct; 67(19):17701-17712. PubMed ID: 39321318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topical Intestinal Aminoimidazole Agonists of G-Protein-Coupled Bile Acid Receptor 1 Promote Glucagon Like Peptide-1 Secretion and Improve Glucose Tolerance.
    Lasalle M; Hoguet V; Hennuyer N; Leroux F; Piveteau C; Belloy L; Lestavel S; Vallez E; Dorchies E; Duplan I; Sevin E; Culot M; Gosselet F; Boulahjar R; Herledan A; Staels B; Deprez B; Tailleux A; Charton J
    J Med Chem; 2017 May; 60(10):4185-4211. PubMed ID: 28414465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of Intestinal Targeted TGR5 Agonists for the Treatment of Type 2 Diabetes.
    Duan H; Ning M; Zou Q; Ye Y; Feng Y; Zhang L; Leng Y; Shen J
    J Med Chem; 2015 Apr; 58(8):3315-28. PubMed ID: 25710631
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Betulinic Acid Derivatives as Potent TGR5 Agonists with Antidiabetic Effects via Humanized TGR5
    Yun Y; Zhang C; Guo S; Liang X; Lan Y; Wang M; Zhuo N; Yin J; Liu H; Gu M; Li J; Xie X; Nan F
    J Med Chem; 2021 Aug; 64(16):12181-12199. PubMed ID: 34406006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of novel TGR5 agonist in combination with Sitagliptin for possible treatment of type 2 diabetes.
    Agarwal S; Sasane S; Kumar J; Deshmukh P; Bhayani H; Giri P; Giri S; Soman S; Kulkarni N; Jain M
    Bioorg Med Chem Lett; 2018 Jun; 28(10):1849-1852. PubMed ID: 29655980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. OL3, a novel low-absorbed TGR5 agonist with reduced side effects, lowered blood glucose via dual actions on TGR5 activation and DPP-4 inhibition.
    Ma SY; Ning MM; Zou QA; Feng Y; Ye YL; Shen JH; Leng Y
    Acta Pharmacol Sin; 2016 Sep; 37(10):1359-1369. PubMed ID: 27264313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study on the mechanism of modified Gegen Qinlian decoction in regulating the intestinal flora-bile acid-TGR5 axis for the treatment of type 2 diabetes mellitus based on macro genome sequencing and targeted metabonomics integration.
    Liu R; Wang J; Zhao Y; Zhou Q; Yang X; Gao Y; Li Q; Bai M; Liu J; Liang Y; Zhu X
    Phytomedicine; 2024 Sep; 132():155329. PubMed ID: 38853123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intestinal TGR5 agonism improves hepatic steatosis and insulin sensitivity in Western diet-fed mice.
    Finn PD; Rodriguez D; Kohler J; Jiang Z; Wan S; Blanco E; King AJ; Chen T; Bell N; Dragoli D; Jacobs JW; Jain R; Leadbetter M; Siegel M; Carreras CW; Koo-McCoy S; Shaw K; Le C; Vanegas S; Hsu IH; Kozuka K; Okamoto K; Caldwell JS; Lewis JG
    Am J Physiol Gastrointest Liver Physiol; 2019 Mar; 316(3):G412-G424. PubMed ID: 30605011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and evaluation of 1-benzyl-1H-imidazole-5-carboxamide derivatives as potent TGR5 agonists.
    Zhao S; Li X; Wang L; Peng W; Ye W; Li W; Wang YD; Chen WD
    Bioorg Med Chem; 2021 Feb; 32():115972. PubMed ID: 33440321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intestinally-targeted TGR5 agonists equipped with quaternary ammonium have an improved hypoglycemic effect and reduced gallbladder filling effect.
    Cao H; Chen ZX; Wang K; Ning MM; Zou QA; Feng Y; Ye YL; Leng Y; Shen JH
    Sci Rep; 2016 Jun; 6():28676. PubMed ID: 27339735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pregnane-Oximino-Alkyl-Amino-Ether Compound as a Novel Class of TGR5 Receptor Agonist Exhibiting Antidiabetic and Anti-Dyslipidemic Activities.
    Gupta J; Singh DP; Verma PC; Rahuja N; Srivastava R; Ahmad I; Jaiswal N; Kumar H; Gupta AP; Gupta V; Misra A; Kushwaha HN; Singh B; Singh SK; Dwivedi AK; Gayen JR; Sanyal S; Srivastava AK; Pratap R; Tamrakar AK
    Pharmacology; 2022; 107(1-2):54-68. PubMed ID: 34814141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery and biological evaluation of novel G protein-coupled receptor 119 agonists for type 2 diabetes.
    Zhou Y; Wang Y; Zhang L; Tang C; Feng B
    Arch Pharm (Weinheim); 2019 Apr; 352(4):e1800267. PubMed ID: 30740769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and antidiabetic activity of 4-phenoxynicotinamide and 4-phenoxypyrimidine-5-carboxamide derivatives as potent and orally efficacious TGR5 agonists.
    Duan H; Ning M; Chen X; Zou Q; Zhang L; Feng Y; Zhang L; Leng Y; Shen J
    J Med Chem; 2012 Dec; 55(23):10475-89. PubMed ID: 23148522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis, and biological evaluations of phenylpropiolic acid derivatives as novel GPR40 agonists.
    Jiang XW; Jiang BE; Liu H; Liu ZT; Hu LL; Liu M; Lu W; Zhang HK
    Eur J Med Chem; 2018 Oct; 158():123-133. PubMed ID: 30212763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beyond the Rule of 5: Impact of PEGylation with Various Polymer Sizes on Pharmacokinetic Properties, Structure-Properties Relationships of mPEGylated Small Agonists of TGR5 Receptor.
    Hoguet V; Lasalle M; Maingot M; Dequirez G; Boulahjar R; Leroux F; Piveteau C; Herledan A; Biela A; Dumont J; Chávez-Talavera O; Belloy L; Duplan I; Hennuyer N; Butruille L; Lestavel S; Sevin E; Culot M; Gosselet F; Staels B; Deprez B; Tailleux A; Charton J
    J Med Chem; 2021 Feb; 64(3):1593-1610. PubMed ID: 33470812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity.
    Wang XX; Wang D; Luo Y; Myakala K; Dobrinskikh E; Rosenberg AZ; Levi J; Kopp JB; Field A; Hill A; Lucia S; Qiu L; Jiang T; Peng Y; Orlicky D; Garcia G; Herman-Edelstein M; D'Agati V; Henriksen K; Adorini L; Pruzanski M; Xie C; Krausz KW; Gonzalez FJ; Ranjit S; Dvornikov A; Gratton E; Levi M
    J Am Soc Nephrol; 2018 Jan; 29(1):118-137. PubMed ID: 29089371
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic potential of Takeda-G-protein-receptor-5 (TGR5) agonists. Hope or hype?
    Hodge RJ; Nunez DJ
    Diabetes Obes Metab; 2016 May; 18(5):439-43. PubMed ID: 26818602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and biological evaluation of novel FFA1/GPR40 agonists: New breakthrough in an old scaffold.
    Li Z; Liu C; Yang J; Zhou J; Ye Z; Feng D; Yue N; Tong J; Huang W; Qian H
    Eur J Med Chem; 2019 Oct; 179():608-622. PubMed ID: 31279294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of Gut-Restricted Thiazolidine Agonists of G Protein-Coupled Bile Acid Receptor 1 (GPBAR1, TGR5).
    Chen T; Reich NW; Bell N; Finn PD; Rodriguez D; Kohler J; Kozuka K; He L; Spencer AG; Charmot D; Navre M; Carreras CW; Koo-McCoy S; Tabora J; Caldwell JS; Jacobs JW; Lewis JG
    J Med Chem; 2018 Sep; 61(17):7589-7613. PubMed ID: 30141927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel GPR120 Agonists with Improved Pharmacokinetic Profiles for the Treatment of Type 2 Diabetes.
    Ji G; Guo Q; Xue Q; Kong R; Wang S; Lei K; Liu R; Wang X
    Molecules; 2021 Nov; 26(22):. PubMed ID: 34833999
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.